3Granville CA,Dennis PA.An overview of lung cancer genomics and proteomics.Am J Respir Cell Mol Biol,2005.32:169-176.
4Gazdar AF.Activating and resistance mutations of EGFR in nonsmall-cell lung cancer:role in clinical response to EGFR tyrosine kinase inhibitors.Oncogene,2009,28:S24-31.
5Bai H,Mao L,Wang HS,et al.Epidermal growth factor receptor mutations in plasma DNA samples predict tumor response in Chinese patients with stages ⅢB to Ⅳ non-small-cell lung cancer.J Clin Oncol,2009,27:2653-2659.
6Lynch TJ,Bell DW,Sordella R,et al.Activating mutations in the epidermal growth factor receptor underlying responsiveness of nonsmall-cell lung cancer to gefitinib.N Engl J Med,2004,350:2129-2139.
7Paez JG,Janne PA,Lee JC,et al.EGFR mutations in lung cancer:correlation with clinical response to gefitinib therapy.Science,2004,304:1497-1500.
8Pao W,Miller V,Zakowski M,et al.EGF receptor gene mutations are common in lung cancers from "never smokers"and are associated with sensitivity of tumors to gefitinib and erlotinib.Proc Natl Acad Sci USA,2004,101:13306-13311.
